<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37112774</PMID><DateRevised><Year>2023</Year><Month>04</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>18</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Safety and Immunogenicity of Enterovirus 71 Vaccine (Vero Cell) Administered Simultaneously with Trivalent Split-Virion Influenza Vaccine in Infants Aged 6-7 Months: A Phase 4, Randomized, Controlled Trial.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">862</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines11040862</ELocationID><Abstract><AbstractText><b>Objective</b>: To assess the immunogenicity and safety of the enterovirus 71 vaccine (Vero cell) (EV71 vaccine) and trivalent split-virion influenza vaccine (IIV3). <b>Methods</b>: Healthy infants aged 6-7 months were recruited from Zhejiang Province, Henan Province, and Guizhou Province and randomly assigned to the simultaneous vaccination group, EV71 group, and IIV3 group at a ratio of 1:1:1. Then, 3 mL blood samples were collected before vaccination and 28 days after the second dose of vaccine. Cytopathic effect inhibition assay was used to detect EV71 neutralization antibody, and cytopathic effect inhibition assay was used to detect influenza virus antibody. <b>Results</b>: A total of 378 infants were enrolled and received the first dose of vaccine and were included in the safety analysis, and 350 infants were involved in the immunogenicity analysis. The adverse events rates were 31.75%, 28.57%, and 34.13% in the simultaneous vaccination group, EV71 group, and IIV3 group (<i>p</i> &gt; 0.05), respectively. No vaccine-related serious adverse events were reported. After two doses of EV71 vaccine, the seroconversion rates of EV71 neutralizing antibody were 98.26% and 97.37% in the simultaneous vaccination group and the EV71 group, respectively. After two doses of IIV3, the simultaneous vaccination group and the IIV3 group, respectively, had seroconversion rates of 80.00% and 86.78% for H1N1 antibody, 99.13% and 98.35% for H3N2 antibody, and 76.52% and 80.99% for B antibody. There was no statistically significant difference in the seroconversion rates of influenza virus antibodies between groups (<i>p</i> &gt; 0.05). <b>Conclusions</b>: The coadministration of EV71 vaccine and IIV3 has good safety and immunogenicity in infants aged 6-7 months.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Yanhui</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Medical Affairs Department, China National Biotec Group Company Limited, No. 2, Shuangqiao Street, Chaoyang District, Beijing 100024, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Xue</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Medical Affairs Department, Changchun Institute of Biological Products Company Limited, Changchun 130012, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medical Affairs Department, China National Biotec Group Company Limited, No. 2, Shuangqiao Street, Chaoyang District, Beijing 100024, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yaping</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Immunisation Programme Department, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yanyang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute for Communicable Disease Control and Prevention, Henan Provincial Center for Disease Control and Prevention, Zhengzhou 450016, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Xiaoqing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute of Expanded Programme on Immunization, Guizhou Provincial Center for Disease Control and Prevention, Guiyang 550004, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Linyun</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Medical Affairs Department, China National Biotec Group Company Limited, No. 2, Shuangqiao Street, Chaoyang District, Beijing 100024, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Haiping</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Medical Affairs Department, China National Biotec Group Company Limited, No. 2, Shuangqiao Street, Chaoyang District, Beijing 100024, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Weichai</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Immunisation Programme Department, Liandu District Center for Disease Control and Prevention, Lishui 323000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Haibo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Immunisation Programme Department, Liandu District Center for Disease Control and Prevention, Lishui 323000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Lixia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Immunisation Programme Department, Boai County Center for Disease Control and Prevention, Jiaozuo 454450, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hou</LastName><ForeName>Renwu</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Immunisation Programme Department, Boai County Center for Disease Control and Prevention, Jiaozuo 454450, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Immunisation Programme Department, Qianxinan Prefecture Center for Disease Control and Prevention, Qianxinan 562400, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Long</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Immunisation Programme Department, Qianxinan Prefecture Center for Disease Control and Prevention, Qianxinan 562400, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruan</LastName><ForeName>Jiewei</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Medical Affairs Department, China National Biotec Group Company Limited, No. 2, Shuangqiao Street, Chaoyang District, Beijing 100024, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Medical Affairs Department, Wuhan Institute of Biological Products Company Limited, Wuhan 430070, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xiaoming</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-2598-4355</Identifier><AffiliationInfo><Affiliation>Medical Affairs Department, China National Biotec Group Company Limited, No. 2, Shuangqiao Street, Chaoyang District, Beijing 100024, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Company Limited, Wuhan 430070, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>EV71-2019MA-01</GrantID><Agency>the China National Biotec Group</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">administered simultaneously</Keyword><Keyword MajorTopicYN="N">enterovirus 71 vaccine (Vero cell)</Keyword><Keyword MajorTopicYN="N">immunogenicity</Keyword><Keyword MajorTopicYN="N">safety</Keyword><Keyword MajorTopicYN="N">trivalent split-virion influenza vaccine</Keyword></KeywordList><CoiStatement>Xiaoming Yang, Yanhui Xiao, Min Zhang, Linyun Luo, Haiping Chen, and Jiewei Ruan are employees of the China National Biotec Group. Xue Guo is the employee of the Changchun Institute of Biological Products. Wei Chen is the employee of the Wuhan Institute of Biological Products. All other authors declare no competing interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>4</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>28</Day><Hour>1</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37112774</ArticleId><ArticleId IdType="pmc">PMC10146551</ArticleId><ArticleId IdType="doi">10.3390/vaccines11040862</ArticleId><ArticleId IdType="pii">vaccines11040862</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Esposito S., Principi N. Hand, foot and mouth disease: Current knowledge on clinical manifestations, epidemiology, aetiology and prevention. Eur. J. Clin. Microbiol. Infect. Dis. 2018;37:391–398. doi: 10.1007/s10096-018-3206-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-018-3206-x</ArticleId><ArticleId IdType="pubmed">29411190</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing W., Liao Q., Viboud C., Zhang J., Sun J., Wu J.T., Chang Z., Liu F., Fang V.J., Zheng Y., et al. Hand, foot, and mouth disease in China, 2008–2012: An epidemiological study. Lancet Infect. Dis. 2014;14:308–318. doi: 10.1016/S1473-3099(13)70342-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(13)70342-6</ArticleId><ArticleId IdType="pmc">PMC4035015</ArticleId><ArticleId IdType="pubmed">24485991</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H., Huang J., Huai Y., Guan X., Klena J., Liu S., Peng Y., Yang H., Luo J., Zheng J., et al. The substantial hospitalization burden of influenza in central China: Surveillance for severe, acute respiratory infection, and influenza viruses, 2010–2012. Influenza Other Respir. Viruses. 2014;8:53–65. doi: 10.1111/irv.12205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.12205</ArticleId><ArticleId IdType="pmc">PMC4177798</ArticleId><ArticleId IdType="pubmed">24209711</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Li Y., O’Brien K.L., Madhi S.A., Widdowson M.A., Byass P., Omer S.B., Abbas Q., Ali A., Amu A., et al. Global burden of respiratory infections associated with seasonal influenza in children under 5 years in 2018: A systematic review and modelling study. Lancet Glob. Health. 2020;8:e497–e510. doi: 10.1016/S2214-109X(19)30545-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(19)30545-5</ArticleId><ArticleId IdType="pmc">PMC7083228</ArticleId><ArticleId IdType="pubmed">32087815</ArticleId></ArticleIdList></Reference><Reference><Citation>Iuliano A.D., Roguski K.M., Chang H.H., Muscatello D.J., Palekar R., Tempia S., Cohen C., Gran J.M., Schanzer D., Cowling B.J., et al. Estimates of global seasonal influenza-associated respiratory mortality: A modelling study. Lancet. 2018;391:1285–1300. doi: 10.1016/S0140-6736(17)33293-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)33293-2</ArticleId><ArticleId IdType="pmc">PMC5935243</ArticleId><ArticleId IdType="pubmed">29248255</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalligeros M., Shehadeh F., Mylona E.K., Dapaah-Afriyie C., van Aalst R., Chit A., Mylonakis E. Influenza vaccine effectiveness against influenza-associated hospitalization in children: A systematic review and meta-analysis. Vaccine. 2020;38:2893–2903. doi: 10.1016/j.vaccine.2020.02.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.02.049</ArticleId><ArticleId IdType="pubmed">32113808</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang L., Wang J., Zhang C., He W., Mo J., Zeng J., Chen M., Tan Y., Ning C. Effectiveness of enterovirus A71 vaccine in severe hand, foot, and mouth disease cases in Guangxi, China. Vaccine. 2020;38:1804–1809. doi: 10.1016/j.vaccine.2019.12.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.12.025</ArticleId><ArticleId IdType="pubmed">31892446</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y.P., Liang Z.L., Gao Q., Huang L.R., Mao Q.Y., Wen S.Q., Liu Y., Yin W.D., Li R.C., Wang J.Z. Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: A randomized, placebo-controlled, double-blind, Phase I clinical trial. Vaccine. 2012;30:3295–3303. doi: 10.1016/j.vaccine.2012.03.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.03.010</ArticleId><ArticleId IdType="pubmed">22426327</ArticleId></ArticleIdList></Reference><Reference><Citation>DiazGranados C.A., Saway W., Gouaux J., Baron M., Baker J., Denis M., Jordanov E., Landolfi V., Yau E. Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50–64 years of age. Vaccine. 2015;33:7188–7193. doi: 10.1016/j.vaccine.2015.10.131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.10.131</ArticleId><ArticleId IdType="pubmed">26555348</ArticleId></ArticleIdList></Reference><Reference><Citation>The European Agency for the Evaluation of Medicinal Products: Committee for proprietary medicinal products (CPMP) Note for Guidance on Harmonization of Requirements for Influenza Vaccines. The European Agency for the Evaluation of Medicinal Products; London, UK: 1997. CPMP/BMW/214/96.</Citation></Reference><Reference><Citation>Wei M., Meng F., Wang S., Li J., Zhang Y., Mao Q., Hu Y., Liu P., Shi N., Tao H., et al. 2-Year Efficacy, Immunogenicity, and Safety of Vigoo Enterovirus 71 Vaccine in Healthy Chinese Children: A Randomized Open-Label Study. J. Infect. Dis. 2017;215:56–63. doi: 10.1093/infdis/jiw502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw502</ArticleId><ArticleId IdType="pubmed">28077584</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu W.W., Meng F.Y., Guo H.J., Hao C.S., Mao Q.Y., Gao F., Bian L.L., Duan K., Chen X.Q., Li X.G. Five-year immunity persistence following immunization with inactivated enterovirus 71 vaccine (Vero cell) Int. J. Biol. 2020;43:261–266. doi: 10.3760/cma.j.cn311962-20200706-00074.</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.cn311962-20200706-00074</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan X.J., Fu J., Shen L.Z., Lv H.K., Xiao Y.H., Chen H.P., Shi X.W. Surveillance results of adverse events following immunization of enterovirus 71 inactvated vaccine. Prev. Med. 2019;31:1097–1099, 1104. doi: 10.19485/j.cnki.issn2096-5087.2019.11.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.19485/j.cnki.issn2096-5087.2019.11.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Head J.R., Collender P.A., Lewnard J.A., Skaff N.K., Li L., Cheng Q., Baker J.M., Li C., Chen D., Ohringer A., et al. Early Evidence of Inactivated Enterovirus 71 Vaccine Impact Against Hand, Foot, and Mouth Disease in a Major Center of Ongoing Transmission in China, 2011-2018: A Longitudinal Surveillance Study. Clin. Infect. Dis. 2020;71:3088–3095. doi: 10.1093/cid/ciz1188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciz1188</ArticleId><ArticleId IdType="pmc">PMC7819528</ArticleId><ArticleId IdType="pubmed">31879754</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z., Liang Z., Zeng J., Zhang J., He P., Su J., Zeng Y., Fan R., Zhao D., Ma W., et al. Immunogenicity and Safety of an Inactivated Enterovirus 71 Vaccine Administered Simultaneously With Hepatitis B Vaccine and Group A Meningococcal Polysaccharide Vaccine: A Phase 4, Open-Label, Single-Center, Randomized, Noninferiority Trial. J. Infect. Dis. 2019;220:392–399. doi: 10.1093/infdis/jiz129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiz129</ArticleId><ArticleId IdType="pubmed">30891604</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Yang W., Zhang C., Wu H., Wang R., Ding Q., Hu Y., Xiong Y., Zhang S., Wang L. Immunogenicity and safety of an inactivated enterovirus 71 vaccine co-administered with measles-mumps-rubella vaccine and live-attenuated Japanese encephalitis vaccine: A phase 4, single-center, randomized controlled trial. Hum. Vaccines Immunother. 2021;17:5348–5354. doi: 10.1080/21645515.2021.2010428.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2021.2010428</ArticleId><ArticleId IdType="pmc">PMC8903949</ArticleId><ArticleId IdType="pubmed">34905446</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Chang S., Wang R., Xiao Y., Li F., Xu Q., Zhang S., Chen X., Zhang S., Zhang M., et al. Immunogenicity and Safety of an Inactivated Enterovirus 71 Vaccine Administered Simultaneously with Hepatitis B Virus Vaccine, Group A Meningococcal Polysaccharide Vaccine, Measles-Rubella Combined Vaccine and Japanese Encephalitis Vaccine: A Multi-Center, Randomized, Controlled Clinical Trial in China. Vaccines. 2022;10:895. doi: 10.3390/vaccines10060895.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10060895</ArticleId><ArticleId IdType="pmc">PMC9230521</ArticleId><ArticleId IdType="pubmed">35746502</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z., Liao Y., Li Y., Jiang G., Huang Z., Yang H., Ou Z., Yin Q., Chen J., Deng Y., et al. Immunogenicity and safety of the inactivated enterovirus 71 vaccine administered concomitantly with the measles-rubella vaccine in infants aged 8 months in China: A noninferiority randomized controlled trial. Vaccine. 2022;40:4709–4715. doi: 10.1016/j.vaccine.2022.06.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.06.027</ArticleId><ArticleId IdType="pubmed">35753838</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B.F., Deng P., Guo X., Zheng N.C., Li Q., Qian X.A., Wang Z., Huang J.F., Chen H.P., Shi X.W., et al. Immunogenicity and safety of a licensed Chinese thimerosal-free trivalent split influenza virus vaccine. Chin. J. Vaccines Immun. 2019;25:180–183, 214.</Citation></Reference><Reference><Citation>Wang Z.G., Sun X., Zhang M., Tang F.Y., Ma F.B., Xu Y., Hu R., Ma Y.L., Xiao Y.L., Chen H.P., et al. Immunogenicity and safety of co-immunization with 23-valent pneumococcal polysaccharide vaccine and influenza virus split vaccine for children aged 3–7 years. Chin. J. Microbiol. Immunol. 2019;39:758–762. doi: 10.3760/cma.j.issn.0254-5101.2019.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.issn.0254-5101.2019.10.006</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>